ATRA enhances the suppressive role of RARα on miR-27a promoter and release the inhibition of miR-27a on GSK-3β leading to laryngeal cancer differentiation through GSK-3β-involved Wnt/β-catenin pathway (Figure 5). Here, RARA is linked to laryngeal carcinoma.